Supplementary Online Content

**Figure S1.** Treatment Preference, Overall and by Baseline MDD

**Table S1.** Treatment Preference by Baseline Demographic, Military Service and Clinical Characteristics

**Table S2.** Dropout by Baseline Demographic, Military Service and Clinical Characteristics

**Appendix S1.** Completer Analyses

**Figure S2.** Cross-sectional Mean PCL and BDI scores: Exposure Therapy and Augmentation Over Time, by Baseline MDD

**Table S3.** Descriptive and Model-estimated Statistics for Secondary Outcomes (PCL): Exposure Therapy and Augmentation Over Time by Baseline MDD

**Table S4.** Descriptive and Model-estimated Statistics for Secondary Outcomes (BDI): Exposure Therapy and Augmentation over Time by Baseline MDD

**Table S5.** Descriptive Statistics for Primary Outcome (CAPS-IV, past week) by Exposure Therapy and Augmentation (combined) Over Time, Overall and by Baseline MDD

**Figure S3.** Descriptive Statistics for Primary Outcome (CAPS-IV, past week) by Exposure Therapy and Augmentation (combined) Over Time, Overall and by Baseline MDD

**Figure S4.** Cross-sectional Mean End-of-session SUDS (Subjective Units of Distress scale) by Augmentation Over Time, Overall and by Baseline MDD

**Appendix S2.** SUDS Analyses (DCS vs. Placebo)
Figure S1. Treatment Preference, Overall and by Baseline MDD

Note. P-values are based on chi-square goodness of fit tests. Overall: preferred VRE, received VRE-51%; preferred PE, received PE-50%, $\chi^2 =0.014$, p=.904. Abbreviations: VRE-virtual reality exposure therapy; PE-prolonged imaginal exposure therapy; MDD-major depressive disorder.
| Demographic characteristics | Preferred, VRE (n=145) | Preferred PE (n=44) | p-value |
|-----------------------------|------------------------|---------------------|---------|
| Age M (SD)                  | 34.28 7.55             | 35.41 8.52          | .403    |
| Male n (%)                  | 132 91.0               | 38 34.4             | .367    |
| Ethnicity/Race n (%)        |                        |                     |         |
| White                       | 69 47.6                | 17 38.6             |         |
| African American/Black      | 21 14.5                | 7 15.9              |         |
| Hispanic/Latino             | 38 26.2                | 15 34.2             |         |
| Other                       | 17 11.7                | 5 11.4              |         |
| Education n (%)             |                        |                     | .787    |
| High school or GED          | 21 14.5                | 8 18.2              |         |
| Some college/training       | 81 55.9                | 22 50.0             |         |
| College graduate            | 26 17.9                | 7 15.9              |         |
| More than college           | 17 11.7                | 7 15.9              |         |
| Relationship status n (%)   |                        |                     | .280    |
| Single                      | 43 29.7                | 14 31.8             |         |
| Married/Live w/significant other | 74 51.0     | 26 59.1             |         |
| Separated/Divorced/Widowed  | 28 19.3                | 4 9.1               |         |
| Military characteristics    |                        |                     | .588    |
| Military service n (%)      |                        |                     |         |
| OEF only                    | 31 21.4                | 8 18.2              |         |
| OIF only                    | 63 43.4                | 23 52.3             |         |
| Both OEF and OIF            | 51 35.2                | 13 29.5             |         |
| Branch of the Armed Forces n (%) |            |                     | .138    |
| Army                        | 81 55.9                | 30 68.2             |         |
| Marines                     | 43 29.7                | 12 27.3             |         |
| Navy                        | 15 10.3                | 0 0                 |         |
| Air Force                   | 6 4.1                  | 2 45.0              |         |
| Other                       | 1 100                  | 0 0                 |         |
| Number of deployments n (%) |                        |                     | .920    |
| 1                           | 51 35.2                | 17 38.6             |         |
| 2                           | 50 34.5                | 16 36.4             |         |
| 3                           | 21 14.5                | 5 11.4              |         |
| 4 or more                   | 23 15.9                | 6 13.6              |         |
| Months in theater M (SD)    | 19.02 12.45            | 19.55 16.50         | .821    |
| Active duty n (%)           | 36 24.8                | 9 20.5              | .551    |
| Clinical characteristics    |                        |                     |         |
| Past PTSD treatment n (%)   | 90 62.1                | 25 56.8             | .532    |
| Baseline MDD n (%)          | 76 52.4                | 25 56.8             | .608    |
| CAPS-IV, past week M(SD)    | 72.77 19.08            | 73.00 20.32         | .946    |
| CAPS-IV, past week, at posttreatment (model-estimated) | 51.02 8.75 | 53.83 7.64 | .102    |

Note. P-values are based on independent samples t-tests or chi-squared tests. Abbreviations: VRE - virtual reality exposure therapy; PE - prolonged imaginal exposure therapy; MDD - major depressive disorder; CAPS-IV - Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale for DSM-IV; OEF and OIF - Operations Iraqi Freedom and Enduring Freedom.
Table S2. Dropout by Baseline Demographic, Military Service and Clinical Characteristics

| Treatment group | Completer n=132 (68.8%) | Dropout n=60 (31.3%) | p-value |
|-----------------|-------------------------|---------------------|---------|
| VRE n (%)       | 70 72.2                | 27 27.8             | .302    |
| PE n (%)        | 62 65.3                | 33 34.7             | .19      |
| DCS n (%)       | 70 73.3                | 25 26.7             | .144    |
| Placebo n (%)   | 62 63.9                | 35 36.1             | .237    |
| VRE+DCS n (%)   | 39 71.0                | 10 29.0             | .0109   |
| PE+DCS n (%)    | 31 62.0                | 19 38.0             | .0109   |
| PE+Placebo n (%)| 31 66.0                | 16 34.0             | .210    |

| Clinical characteristics | Completer n=132 | Dropout n=60 | p-value |
|--------------------------|----------------|-------------|---------|
| Baseline MDD n (%)       | 70 67.3       | 34 32.7     | .639    |
| No Baseline MDD n (%)    | 62 70.5       | 26 29.5     |         |
| VRE n (%)                | 36 66.7       | 17 33.3     | .885    |
| PE n (%)                 | 34 68.0       | 16 32.0     |         |
| DCS n (%)                | 38 73.1       | 14 26.9     | .210    |
| Placebo n (%)            | 32 61.5       | 20 38.5     |         |
| No Baseline MDD VRE n (%)| 34 79.1       | 9 20.9      | .083    |
| No Baseline MDD PE n (%) | 28 62.2       | 17 37.8     |         |
| No Baseline MDD DCS n (%)| 32 74.4       | 11 25.6     | .426    |
| No Baseline MDD Placebo n (%)| 30 66.7 | 15 33.3 |         |
| VRE+DCS n (%)            | 22 80.8       | 6 19.2      | .478    |
| PE+DCS n (%)             | 18 62.1       | 11 37.9     |         |
| PE+Placebo n (%)         | 21 63.6       | 8 36.4      |         |
| CAPS-IV, past week M(SD) | 72.82 19.59   | 73.52 19.35  | .818    |
| Physical or sexual trauma n (%) | 77 62.6 | 46 37.4 | .019    |
| No physical or sexual trauma n (%) | 53 79.1 | 14 20.9 |         |

| Demographic characteristics | Completer n=132 | Dropout n=60 | p-value |
|-----------------------------|----------------|-------------|---------|
| Age M (SD)                  | 35.09 8.18     | 33.56 6.80  | .181    |
| Male n (%)                  | 119 69.2       | 53 30.8     | .702    |
| Female n (%)                | 13 65.0        | 7 35.0      |         |
| White n (%)                 | 67 76.1        | 21 23.9     |         |
| African American/Black n (%)| 21 72.4        | 8 27.6      |         |
| Hispanic/Latino n (%)       | 30 56.6        | 23 43.4     |         |
| Other n (%)                 | 14 63.6        | 8 36.4      |         |
| Education n (%)             | 18 62.1        | 11 37.9     |         |
| High school or GED n (%)    | 66 63.5        | 38 36.5     |         |
| Some college/training n (%)| 27 81.8        | 6 18.2      |         |
| College graduate n (%)      | 21 80.8        | 5 19.2      |         |
| More than college n (%)     | 40 67.8        | 19 32.2     |         |
| Relationship status n (%)   | 67 67.0        | 33 33.0     |         |
| Single n (%)                | 25 78.1        | 7 21.9      |         |

| Military characteristics | Completer n=132 | Dropout n=60 | p-value |
|--------------------------|----------------|-------------|---------|
| Military Service n (%)   | 24 61.5       | 15 38.5     | .074    |
| OEF only n (%)            | 55 64.0       | 31 36.0     |         |
| OIF only n (%)            | 53 79.1       | 14 20.9     |         |
| Both OEF and OIF n (%)    | 53 79.1       | 14 20.9     |         |
| Number of deployments n (%)| 1 49.1 | 21 30.9 | .961    |
| 1                          | 2               |             |         |
| 2                          | 45 68.2        | 21 31.8     |         |
| 3                          | 17 65.4        | 9 34.6      |         |
| 4 or more                  | 22 71.9        | 9 28.1      |         |
| Months in theater M(SD)    | 12.1 12.7      | 12 12.1     | .685    |
| Active duty n (%)          | 36 78.3        | 10 21.7     | .111    |
| Non-Active duty n (%)      | 96 65.8        | 50 34.2     |         |

| Treatment preference and Treatment received, Treatment satisfaction | Completer n=132 | Dropout n=60 | p-value |
|---------------------------------------------------------------------|----------------|-------------|---------|
| Preferred VRE n (%)       | 99 68.3        | 46 31.7     | .785    |
| Preferred PE n (%)        | 31 70.5        | 13 29.5     | .129    |
| Preferred VRE, received VRE n (%) | 53 71.6 | 21 28.4 | .612    |
| Preferred PE, received PE n (%) | 14 63.6 | 8 36.4 |         |
| Preferred VRE, received PE n (%) | 46 64.8 | 25 35.2 |         |
| Preferred PE, received VRE n (%) | 31 70.5 | 13 29.5 |         |
| Treatment satisfaction M(SD) | 28.58 3.33    | 27.23 5.34  | .387    |

Note: P-values are based on independent samples t-tests or chi-squared tests. Treatment satisfaction for dropouts is based on the last satisfaction rating available. Abbreviations: VRE-virtual reality exposure therapy; PE-prolonged imaginal exposure therapy; DCS- D-Cycloserine; MDD-major depressive disorder; SSRI Selective serotonin reuptake inhibitor; CAPS-IV- Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale for DSM-IV; OEF and OIF - Operations Iraqi Freedom and Enduring Freedom.
Appendix S1. Completer Analyses. Identical to ITT findings, completer analyses suggested PE was more effective for non-depressed participants (model estimated mean CAPS difference at posttreatment for completers M=12.01, p<.001, ES=.60) but VRE was more effective for depressed subjects (model estimated mean CAPS difference at posttreatment M=7.65, p<.001, ES=.31). Furthermore, there was a significant effect of time (F=44.09, p<.001), a non-significant effect for augmentation (F=.132, p=.716) and a non-significant augmentation by time interaction (F=.422, p=.517). There was a significant main effect of baseline MDD (F=19.60, p<.001) and a marginally significant augmentation by MDD interaction (F=2.97, p=.087) suggesting that depressed participants improved more on placebo (model estimated mean CAPS difference at posttreatment M=10.55, p<.001, ES=.53. However, DCS was slightly more effective for completer participants who were non-depressed (model estimated mean CAPS difference at posttreatment M=4.26, p=.035, ES=.17).
Figure S2. Cross-sectional Mean PCL and BDI scores: Exposure Therapy and Augmentation Over Time, by Baseline MDD

Note. Bars represent standard errors. Abbreviations: VRE-virtual reality exposure therapy; PE-prolonged imaginal exposure therapy; DCS-D-Cycloserine; MDD-major depressive disorder.
Table S3. Descriptive and Model-estimated Statistics for Secondary Outcomes (PCL): Exposure Therapy and Augmentation Over Time by Baseline MDD

|                  | Exposure Therapy (VRE vs. PE) | Augmentation (DCS vs. Placebo) |
|------------------|-------------------------------|---------------------------------|
|                  | VRE n=97                      | PE n=95                         |
| Overall          | N    M    SD    N    M    SD  | N    M    SD    N    M    SD |
| Baseline         | 95   53.35 12.56  93   54.43 12.89 |
| After session 4  | 78  52.03 14.96  69   48.25 15.03 |
| After session 6  | 72  45.82 15.92  64   44.92 15.83 |
| Posttreatment    | 67  40.01 14.94  56   41.16 16.41 |
| 3-month Follow-up| 61  42.38 15.97  50   42.64 17.72 |
| Baseline         | 52   57.33 11.50  49   59.45 9.90  |
| After session 4  | 43   51.95 15.36  38   54.03 14.86  |
| After session 6  | 39   45.38 17.01  36   49.72 15.72  |
| Posttreatment    | 34   38.85 15.48  32   47.19 16.26  |
| 3-month Follow-up| 31   42.06 17.92  27   48.85 19.19  |

**MDD**

|                  | N    M    SD    N    M    SD  | N    M    SD    N    M    SD |
| Baseline         | 43   48.53 12.22  44   48.84 13.62  |
| After session 4  | 35   52.11 14.69  31   41.16 12.07  |
| After session 6  | 33   46.33 14.77  28   38.75 13.94  |
| Posttreatment    | 33   41.21 14.51  24   33.13 13.05  |
| 3-month Follow-up| 30   42.70 13.99  23   35.35 12.70  |

**No MDD**

|                  | N    M    SD    N    M    SD  | N    M    SD    N    M    SD |
| Baseline         | 43   48.53 12.22  44   48.84 13.62  |
| After session 4  | 35   52.11 14.69  31   41.16 12.07  |
| After session 6  | 33   46.33 14.77  28   38.75 13.94  |
| Posttreatment    | 33   41.21 14.51  24   33.13 13.05  |
| 3-month Follow-up| 30   42.70 13.99  23   35.35 12.70  |

**PCL**

|                  | Mean difference (VRE vs. PE) | 95%CI  | p-value | ES  | Mean difference (DCS vs. Placebo) | 95%CI  | p-value | ES  |
|------------------|-----------------------------|--------|---------|-----|----------------------------------|--------|---------|-----|
| MDD Intent-to-treat analysis | 3.98 (1.68, 6.28) | 0.001 | 0.30 | -4.40 (-6.78, -2.02) | <.001 | -0.33 |
| No MDD Intent-to-treat analysis | -2.71 (-5.04, -0.39) | 0.023 | -0.21 | 3.57 (1.20, 5.94) | 0.004 | 0.28 |

Note. aModel-estimated statistics are based on mixed effects linear regression models examining change in PCL scores over time (baseline, after sessions 4 and 6, and posttreatment) with random intercepts and unstructured covariance structure. Intent to treat analysis PCL: Exposure therapy (VRE vs. PE) by MDD interaction p-value = .091; augmentation (DCS vs. placebo) by MDD interaction p-value = .021. ES- standardized effect size (model-estimated between-group differences divided by the common standard deviation of the PCL changes scores baseline-posttreatment). Abbreviations: VRE-virtual reality exposure therapy; PE-prolonged imaginal exposure therapy; DCS- D-Cycloserine; MDD-major depressive disorder.
### Table S4. Descriptive and Model-estimated Statistics for Secondary Outcomes (BDI): Exposure Therapy and Augmentation over Time by Baseline MDD

|                     | Exposure Therapy (VRE vs. PE) | Augmentation (DCS vs. Placebo) |
|---------------------|--------------------------------|---------------------------------|
|                     | VRE n=97                       | PE n=95                         | DCS n=95                       | Placebo n=97                      |
| **BDI**             | **Descriptive Statistics**     | **Descriptive Statistics**      |                                |                                |
|                     | N  | M   | SD  | N  | M   | SD  | N  | M   | SD  | N  | M   | SD  | N  | M   | SD  |
| Baseline            | 94 | 21.49| 9.26| 93 | 21.81| 10.24| 93 | 21.22| 9.96| 94 | 22.07| 9.54|
| After session 4     | 78 | 20.56| 9.85| 69 | 19.17| 11.35| 74 | 19.47| 10.41| 73 | 20.36| 10.78|
| After session 6     | 72 | 18.19| 10.34| 64 | 17.14| 10.79| 69 | 17.26| 9.90 | 67 | 18.15| 11.19|
| Posttreatment       | 67 | 15.03| 9.37| 56 | 16.70| 11.63| 66 | 15.59| 10.36| 57 | 16.02| 10.63|
| 3-month Follow-up   | 61 | 15.92| 10.93| 50 | 16.16| 12.37| 59 | 16.31| 11.35| 52 | 15.71| 11.88|
| **MDD**             | **Descriptive Statistics**     |                                |                                |                                |
|                     | N  | M   | SD  | N  | M   | SD  | N  | M   | SD  | N  | M   | SD  | N  | M   | SD  |
| Baseline            | 52 | 25.02| 8.56| 49 | 27.84| 8.52| 51 | 26.08| 8.43| 50 | 26.70| 8.87|
| After session 4     | 43 | 22.02| 11.36| 38 | 24.79| 11.23| 41 | 23.37| 10.81| 40 | 23.28| 11.95|
| After session 6     | 39 | 19.23| 11.63| 36 | 22.56| 10.36| 38 | 20.66| 9.78| 37 | 21.00| 12.43|
| Posttreatment       | 34 | 15.18| 10.52| 32 | 21.34| 11.27| 37 | 19.19| 10.78| 29 | 16.86| 11.87|
| 3-month Follow-up   | 31 | 17.45| 13.09| 27 | 20.93| 13.23| 31 | 20.65| 11.97| 27 | 17.26| 14.43|
| **No MDD**          | **Descriptive Statistics**     |                                |                                |                                |
|                     | N  | M   | SD  | N  | M   | SD  | N  | M   | SD  | N  | M   | SD  | N  | M   | SD  |
| Baseline            | 42 | 17.12| 8.24| 44 | 15.09| 7.48| 42 | 15.31| 8.40| 44 | 16.82| 7.37|
| After session 4     | 35 | 18.77| 7.36| 31 | 12.29| 6.91| 33 | 14.64| 7.58| 33 | 16.82| 8.00|
| After session 6     | 33 | 16.97| 8.57| 28 | 10.18| 6.56| 31 | 13.10| 8.47| 30 | 14.63| 8.36|
| Posttreatment       | 33 | 14.88| 8.17| 24 | 10.50| 9.06| 29 | 11.00| 7.80| 28 | 15.14| 9.32|
| 3-month Follow-up   | 30 | 14.33| 8.05| 23 | 10.57| 8.55| 28 | 11.50| 8.48| 25 | 14.04| 8.28|
| **Model-estimated statistics* at posttreatment** | | | | | | | | | | | | |
|                     | Mean difference (VRE vs. PE) | 95%CI | p-value | ES | Mean difference (DCS vs. Placebo) | 95%CI | p-value | ES |
| **MDD**             | | | | | | | | | | | | |
| Intent-to-treat analysis | 4.20 | (2.79, 5.62) | <.001 | 0.46 | | | | | | |
| No MDD              | | | | | | | | | | | | |
| Intent-to-treat analysis | -2.56 | (-4.05, -1.08) | 0.001 | -0.36 | | | | | | |

Note. *Model-estimated statistics are based on mixed effects linear regression models examining change in BDI scores over time (baseline, after sessions 4 and 6, and posttreatment) with random intercepts and unstructured covariance structure. Intent to treat analysis BDI: Exposure therapy (VRE vs. PE) by MDD interaction p-value = .012; augmentation (DCS vs. placebo) by MDD interaction p-value = .241. ES- standardized effect size (model-estimated between-group differences divided by the common standard deviation of the BDI changes scores baseline-posttreatment).
Table S5. Descriptive Statistics for Primary Outcome (CAPS-IV, past week) by Exposure Therapy and Augmentation (combined) Over Time, Overall and by Baseline MDD

|                    | PE+Placebo  | PE+DCS     | VRE+Placebo | VRE+DCS     |
|--------------------|-------------|------------|-------------|-------------|
|                    | n=47        | n=48       | n=50        | n=47        |
| CAPS-IV; past week |             |            |             |             |
| Overall            |             |            |             |             |
| Baseline           | 47          | 70.74      | 20.37       | 48          | 75.08      | 18.69       | 50          | 74.46      | 19.11       | 47          | 71.72      | 19.98       |
| After session 4    | 36          | 66.39      | 24.54       | 32          | 77.56      | 23.40       | 40          | 77.08      | 20.04       | 41          | 76.63      | 19.98       |
| After session 6    | 33          | 61.39      | 26.98       | 31          | 68.42      | 26.52       | 34          | 62.71      | 23.28       | 39          | 63.21      | 24.41       |
| Posttreatment      | 31          | 44.16      | 23.15       | 30          | 57.27      | 25.90       | 30          | 53.17      | 25.82       | 39          | 51.85      | 27.43       |
| 3-month Follow-up  | 26          | 40.46      | 25.64       | 26          | 60.23      | 29.11       | 28          | 50.64      | 27.26       | 36          | 47.78      | 25.51       |
| MDD                |             |            |             |             |
| Baseline           | 25          | 78.16      | 18.53       | 25          | 85.64      | 15.39       | 27          | 79.15      | 17.15       | 27          | 77.74      | 17.55       |
| After session 4    | 19          | 74.26      | 24.70       | 19          | 88.84      | 15.98       | 23          | 77.00      | 21.80       | 22          | 79.68      | 23.11       |
| After session 6    | 18          | 68.39      | 24.21       | 18          | 78.67      | 22.84       | 19          | 59.89      | 24.61       | 20          | 66.25      | 26.79       |
| Posttreatment      | 16          | 53.50      | 23.40       | 18          | 69.11      | 22.66       | 15          | 47.67      | 27.21       | 20          | 57.00      | 30.38       |
| 3-month Follow-up  | 13          | 45.46      | 30.65       | 15          | 72.93      | 24.35       | 14          | 50.21      | 29.36       | 17          | 54.06      | 30.00       |
| No MDD             |             |            |             |             |
| Baseline           | 22          | 62.32      | 19.42       | 23          | 63.61      | 14.97       | 23          | 68.96      | 20.18       | 20          | 63.60      | 20.59       |
| After session 4    | 17          | 57.59      | 21.79       | 13          | 61.08      | 23.14       | 17          | 77.18      | 18.03       | 19          | 73.11      | 15.47       |
| After session 6    | 15          | 53.00      | 28.52       | 13          | 54.23      | 25.37       | 15          | 66.27      | 21.79       | 19          | 60.00      | 21.88       |
| Posttreatment      | 15          | 34.20      | 18.87       | 12          | 39.50      | 20.03       | 15          | 58.67      | 24.00       | 19          | 46.42      | 23.53       |
| 3-month Follow-up  | 13          | 35.46      | 19.39       | 11          | 42.91      | 26.76       | 14          | 51.07      | 26.11       | 19          | 42.16      | 19.85       |

Note: Abbreviations: VRE-virtual reality exposure therapy; PE-prolonged imaginal exposure therapy; DCS-D-Cycloserine; CAPS-IV- Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale for DSM-IV; MDD-major depressive disorder.
Figure S3. Descriptive Statistics for Primary Outcome (CAPS-IV, past week) by Exposure Therapy and Augmentation (combined) Over Time, Overall and by Baseline MDD

Note: Abbreviations: VRE-virtual reality exposure therapy; PE-prolonged imaginal exposure therapy; DCS-D-Cycloserine; CAPS-IV- Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale for DSM-IV; MDD-major depressive disorder.
Figure S4. Cross-sectional Mean End-of-session SUDS (Subjective Units of Distress scale) by Augmentation Over Time, by Baseline MDD

Appendix S2. SUDS Analyses (DCS vs. Placebo). We focused on the analysis of the between session extinction (as measure by end-of-session SUDS), since recent literature suggests that between session extinction is the primary mechanisms underlying exposure therapy for the treatment of PTSD (Rauch et al., 2018).

Multilevel modeling (SUDS nested within person over time) was used to evaluate patterns of between-session extinction in the DCS and placebo groups overall and by MDD status. Models included fixed effects of time (session number), group (DCS vs. placebo) and time by group interaction. Baseline MDD status was included as a fixed effect. Models were then stratified by MDD status, following a significant MDD effect. Next CAPS change from baseline to posttreatment was added as a fixed effect.

Findings indicate that end-of-session SUDS decreased over time (session effect p<.001, average decrease was 18.11 points). There was no significant effect of the medication (DCS vs. placebo) on the reduction in end-of-session SUDS over the course of the treatment (interaction p-value >.05, reduction from session 3 to session 9 in DCS group was 15.02 points, reduction in placebo group was 21.22 points). Among participants without MDD (MDD-), end-of-session SUDS decrease over time was similar between DCS and placebo groups (22.97 points and 17.96, respectively). Among participants with MDD (MDD+), end-of-session SUDS decrease over time was 23.31 points in the placebo group, compared to only 8.66 points in DCS group (Figures S4). Overall, symptoms reduction (CAPS change from baseline to posttreatment) was associated with a decrease in between-session habituation (p=.007). However, this was evident among participants without depression (p=.007) but not among participants with depression (p=.206).

Note: Abbreviations: SUDS-(Subjective Units of Distress Scale, 0=no anxiety and 100=maximum anxiety); DCS- D-Cycloserine; MDD-major depressive disorder.